Article Text

PDF
FRI0604 Successful treatment of arthritis induced by checkpoint inhibitors with anti–interleukin-6 receptor antibody: a case series
  1. ST Kim1,
  2. A Diab2,
  3. M Uemura2,
  4. S Garcia3,
  5. P Hwu2,
  6. J Tayar1
  1. 1Rheumatology
  2. 2Melanoma Medical Oncology, MD Anderson Cancer Center
  3. 3Rheumatology, Baylor College of Medicine, Houston, United States

Abstract

Background Immune checkpoint inhibitors (CPIs) have significantly improved outcomes for patients with various cancers. However, CPIs are associated with immune-related adverse events (irAEs). Two to three percent of patients receiving a CPI develop arthritis. In general, severe irAEs are treated with a high-dose steroid and a tumor necrosis factor inhibitor (TNFi), usually infliximab; however, TNFi treatment is sometimes contraindicated and, furthermore, entails a theoretical concern of impairing antitumor immunity. Therefore, evidence showing the clinical benefits of non-TNFi biologics in the treatment of irAEs is of immediate interest.

Objectives We described the effects of anti-IL-6R antibody for the treatment of arthritis-irAE.

Methods Three patients receiving CPI developed arthritis and were treated with anti-IL-6R antibody. Patients were followed up to 15 months.

Results All patients had metastatic melanoma (Table 1). No patient had a history of autoimmune disease at the time of initiation of CPI treatment. One patient developed arthritis 8 weeks after the completion of anti-CTLA-4 antibody treatment. Two patients were receiving anti-PD-1 antibody when they developed arthritis. Patient 2 continued to receive anti-PD-1 antibody despite of arthritis-irAE while patient 3 discontinued anti-PD-1 antibody due to arthritis-irAE. The pattern of arthritis was symmetric polyarthritis involving small and large joints. Patient 1 had a positive rheumatoid factor (unknown baseline) and patient 3 had a positive ANA (known positive prior to CPI treatment). All patients were treated with anti-IL-6R antibody, which was well tolerated. All patients experienced a 40–100% reduction in global assessment, swollen joint count, and tender joint count, and these effects were maintained for up to 15 months of treatment (Figure 1). As of December 2016, all patients were alive; one patient was in complete remission and two patients had experienced progression of their melanoma.

Table 1.

Patient demographic and clinical characteristics

Conclusions These three cases suggest that anti-IL-6R antibody is an effective alternative to TNFi for the treatment of arthritis-irAE.

Acknowledgements None

Disclosure of Interest None declared

Statistics from Altmetric.com

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.